Curr Oncol. 2015 Jun;22(3):e164-70. doi: 10.3747/co.22.2339.

Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified.

Current oncology (Toronto, Ont.)

C Ho, K M Tong, K Ramsden, D N Ionescu, J Laskin

PMID: 26089727 PMCID: PMC4462538 DOI: 10.3747/co.22.2339

Abstract

BACKGROUND: The importance of histologic classification in selecting the appropriate systemic therapy for non-small-cell lung cancer (nsclc) came to attention in 2007. In British Columbia, that information was communicated through international and national meetings, our centralized cancer care program, and to the medical community at large in multidisciplinary forums. We examined the effects of those education programs on the categorization of nsclc and associated systemic treatment practices.

METHODS: The BC Cancer Agency provides cancer care to 4.6 million residents of British Columbia. A retrospective review of all stage iiib and ivnsclc patients referred in 2007 and 2011 collected baseline characteristics, treatment, and outcomes. Histology was classified using the International Classification of Diseases for Oncology, 3rd edition, for the Canadian Cancer Registry.

RESULTS: In 2007, 671 patients were referred, and 170 received chemotherapy; in 2011, the relevant figures were 680 and 197 respectively. Baseline characteristics in the cohorts were not statistically significantly different in 2007 and 2011. Histologic classifications in 2007 were 41% nonsquamous, 13% squamous, and 46% not otherwise specified (nos); in 2011, they were 63%, 17%, and 20% respectively. Exposure to pemetrexed in any line of therapy in 2007 was 22% for nonsquamous, 17% for squamous, and 10% for nos; in 2011, exposure was 39%, 3%, and 37% respectively. Exposure to epidermal growth factor receptor tyrosine kinase inhibitor (egfrtki) in 2007 was 36%, 22%, and 33%; in 2011, it was 64%, 60%, and 63%. Median overall survival duration, 2007 versus 2011, was 3.25 months versus 3.57 months with best supportive care, and 11.31 months versus 11.54 months with chemotherapy.

CONCLUSIONS: The specificity of nsclc histologic categorization improved in 2011 compared with 2007, with a reduction of 26 percentage points in the rate of nos disease. The proportion of patients treated with chemotherapy over time remained the same, but the use of pemetrexed and egfrtki increased. The increased accuracy in histologic classification resulted in more appropriate utilization of systemic drugs.

Keywords: Histology; lung cancer; nonsquamous; nos; squamous; systemic therapy

References

1. J Clin Oncol. 2013 Sep 20;31(27):3327-34 - PubMed
2. Lancet Oncol. 2013 Sep;14 (10 ):981-8 - PubMed
3. J Clin Oncol. 2008 Jul 20;26(21):3543-51 - PubMed
4. J Thorac Oncol. 2009 Oct;4(10):1202-11 - PubMed
5. Lung Cancer. 2012 Sep;77(3):501-6 - PubMed
6. Lancet. 2008 Nov 22;372(9652):1809-18 - PubMed
7. Lung Cancer. 2012 Dec;78(3):245-52 - PubMed
8. J Thorac Oncol. 2010 Oct;5(10):1529-35 - PubMed
9. Lancet Oncol. 2012 Mar;13(3):239-46 - PubMed
10. J Clin Oncol. 2002 Apr 1;20(7):1786-92 - PubMed
11. J Thorac Oncol. 2012 Jan;7(1):57-63 - PubMed
12. Oncologist. 2009 Mar;14(3):253-63 - PubMed
13. N Engl J Med. 2002 Jan 10;346(2):92-8 - PubMed
14. N Engl J Med. 2013 Jun 20;368(25):2385-94 - PubMed
15. Lancet Oncol. 2012 Mar;13(3):300-8 - PubMed
16. J Clin Oncol. 2009 Mar 10;27(8):1227-34 - PubMed
17. Lung Cancer. 2013 Jul;81(1):47-52 - PubMed
18. N Engl J Med. 2005 Jul 14;353(2):123-32 - PubMed
19. Lancet Oncol. 2012 Mar;13(3):247-55 - PubMed
20. BMJ. 1995 Oct 7;311(7010):899-909 - PubMed
21. J Thorac Oncol. 2011 Feb;6(2):244-85 - PubMed
22. N Engl J Med. 2009 Sep 3;361(10):947-57 - PubMed
23. Lung Cancer. 2012 Dec;78(3):263-9 - PubMed
24. Oncologist. 2011;16(9):1307-15 - PubMed
25. N Engl J Med. 2006 Dec 14;355(24):2542-50 - PubMed
26. Lancet. 2009 Oct 24;374(9699):1432-40 - PubMed
27. Lancet Oncol. 2010 Jun;11(6):521-9 - PubMed

Publication Types

• Journal Article